Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD4 | P21917 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 7/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 4/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700236 | 0.92 | HPGDS (0.46) | DRD2DRD4HTR2AHPGDSCTSL | |
| SCHEMBL6702842 | 0.91 | CTSL (0.39) | DRD2DRD4HTR2AHPGDSCTSL | |
| SCHEMBL6702085 | 0.90 | HPGDS (0.45) | DRD2DRD4HTR2AHPGDSCTSL | |
| SCHEMBL6704289 | 0.90 | HPGDS (0.47) | DRD2DRD4HTR2AHPGDSCTSL | |
| SCHEMBL6703064 | 0.90 | HPGDS (0.47) | DRD2DRD4HTR2AHPGDSCTSL | |
| SCHEMBL6294295 | 0.86 | CTSL (0.40) | CTSLCYP2D6CYP2C9 | |
| SCHEMBL6702836 | 0.86 | CTSL (0.41) | CTSLCTSSCTSBCTSKKLKB1 | |
| SCHEMBL6699255 | 0.85 | CTSL (0.40) | CTSLCTSSCTSBCTSKKLKB1 | |
| SCHEMBL6695685 | 0.84 | CTSB (0.45) | CTSLCTSSCTSBCTSKKLKB1 | |
| SCHEMBL6703752 | 0.84 | CTSK (0.47) | HPGDSCTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1358176-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057246-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | DRD2 4621/4885DRD4 4692/4885HTR2A 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.